Summary
GBI Research, the leading business intelligence provider, has released its latest research “Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth”. The report provides in-depth analysis of drivers and barriers that impact the global hospital acquired bacterial infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Scope
The scope of this report includes:
- Annualized market data for the HABI market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Eli Lily, Astrazeneca, Hoffman-La-Roche, Abbott, Novo Nordisk and Warner and Chilcott.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.
For more information, please visit:
http://www.aarkstore.com/reports/Hospital-Acquired-Bacterial-Infections-Market-to-2016-Increasing-Antibiotic-Resistance-and-Increasing-Population-of-Critically-Ill-Patients-To-Drive-Growth-91887.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
GBI Research, the leading business intelligence provider, has released its latest research “Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth”. The report provides in-depth analysis of drivers and barriers that impact the global hospital acquired bacterial infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Scope
The scope of this report includes:
- Annualized market data for the HABI market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Eli Lily, Astrazeneca, Hoffman-La-Roche, Abbott, Novo Nordisk and Warner and Chilcott.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.
For more information, please visit:
http://www.aarkstore.com/reports/Hospital-Acquired-Bacterial-Infections-Market-to-2016-Increasing-Antibiotic-Resistance-and-Increasing-Population-of-Critically-Ill-Patients-To-Drive-Growth-91887.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
No comments:
Post a Comment